Targeting of ligand binding sites in ClfA
AssigneeThe Texas A&M University System
InventorsVannakambadi K. Ganesh, Magnus Hook
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.
Claims11
A method of determining the presence of gram positive bacteria in a test sample, comprising the steps of:
- providing a test sample;
- contacting the test sample with an antibody that specifically binds to a portion of a N3 fibrinogen binding site of Clumping factor A protein (ClfA), wherein the N3 fibrinogen binding site is selected from the group consisting SEQ ID No:
- 15, SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, wherein the binding of the antibody to the N3 fibrinogen binding site reduces binding of fibrinogen to the ClfA, and wherein the antibody contains a detectable label;
- binding the gram positive bacteria to the antibody;
- and detecting the presence of gram positive bacteria in the test sample based on the signal generated by the detectable label, wherein the signal generated by the detectable label correlates with the presence of gram positive bacteria, and wherein the unbound labeled antibody is removed prior to assessment of binding.
A method of using a pharmaceutical composition for treating, preventing or reducing a gram positive bacterial infection in a patient comprising:
- administering an effective amount of the pharmaceutical composition to the patient for decreasing the severity of gram positive bacteria-associated sepsis in the patient;
- delaying the onset of sepsis associated with gram positive bacterial infections in the patient;
- preventing the onset of sepsis associated with gram positive bacterial infections in the patient;
- reducing gram positive bacterial load in the bloodstream or heart in the patient;
- reducing gram positive bacterial agglutination and/or thromboembolic lesion formation in the patient;
- or preventing gram positive bacterial infections in the patient, wherein the pharmaceutical composition comprises an antibody that binds to a portion of a N3 fibrinogen binding site of Clumping factor A protein (ClfA), wherein the portion of the N3 fibrinogen binding site that the antibody binds to is selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, and wherein the binding of the antibody to the N3 fibrinogen binding site reduces binding of fibrinogen to the ClfA.
A composition comprising a peptide of S. aureus Clumping factor A protein (ClfA), wherein the peptide comprises a fibrinogen binding site and the peptide is SEQ ID NO:17.
Dependencies are inferred from the claim text.